Markets

Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%

An image of a person looking at financial reports
Credit: Shutterstock photo

Pharmaceutical giant Allergan AGN announced on Monday they will acquire ZELTIQ Aesthetics ZLTQ in a $2.47 billion deal. Allergan expects the deal to close in the latter half of 2017.

ZELTIQ, a medical technology company, focuses on commercializing their proprietary controlled-cooling technology. Their first commercial product is the CoolSculpting System, designed to reduce fat. The system is based on the scientific principle that fat cells are more sensitive to cold compared to their surrounding tissues and skin. The technology treats areas with controlled cooling to reduce the temperature of the fat cells which is intended to eliminate fat cells through a natural biological process named apoptosis.

Allergan plans to integrate ZELTIQ's best-in-class body contouring business with their facial aesthetics, plastic surgery and regenerative medicine business. Body contouring is a $4 billion global market opportunity for Allergen to actualize.

On news of the deal, both Allergan and ZELTIQ shares are up 0.43% and 13.46%, respectively. The deal represents a 14.4% premium on ZELTIQ's Friday closing price of $49.40.

On news of the acquisition, CEO of ZELTIQ, Mark Foley, stated, "Allergan's world-class medical aesthetics products, global footprint, history and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to realize the maximum commercial potential of the ZELTIQ controlled-cooling technology platform".

The acquisition of ZELTIQ is the latest of Allergan's deal making. Allergan attempted to acquire Pfizer PFE in 2016 for $160 billion. The deal died in early April due to the Obama administration tightening policy to prevent U.S. corporations from moving their tax headquarters overseas as Allergan is headquartered in Ireland and Pfizer in New York.

Long-Term Buys You Won't See in the News

The stocks you see in today's headlines may not be in the news tomorrow or next week. If you're looking for profitable long-term investments, you may be interested to see what Zacks Research is recommending to our private members. These moves have double and triple-digit profit potential. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this exclusive information? Click here>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer, Inc. (PFE): Free Stock Analysis Report

Allergan PLC. (AGN): Free Stock Analysis Report

ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More